Gabapentin For the Control of Hot Flashes in Women With Breast Cancer

NACompletedINTERVENTIONAL
Timeline

Start Date

July 31, 2001

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions
Anxiety DisorderBreast CancerDepressionHot Flashes
Interventions
DRUG

gabapentin

PROCEDURE

quality-of-life assessment

Trial Locations (18)

11030

CCOP - North Shore University Hospital, Manhasset

13217

CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., Syracuse

36688

MBCCOP - Gulf Coast, Mobile

43206

CCOP - Columbus, Columbus

45429

CCOP - Dayton, Dayton

54449

CCOP - Marshfield Medical Research and Education Foundation, Marshfield

55416

CCOP - Metro-Minnesota, Saint Louis Park

62526

CCOP - Central Illinois, Decatur

80224

CCOP - Colorado Cancer Research Program, Incorporated, Denver

96813

MBCCOP - Hawaii, Honolulu

98101

CCOP - Virginia Mason Research Center, Seattle

85006-2726

CCOP - Greater Phoenix, Phoenix

85259-5404

CCOP - Scottsdale Oncology Program, Scottsdale

67214-3882

CCOP - Wichita, Wichita

49007-3731

CCOP - Kalamazoo, Kalamazoo

07601

CCOP - Northern New Jersey, Hackensack

27104-4241

CCOP - Southeast Cancer Control Consortium, Winston-Salem

98405-0986

CCOP - Northwest, Tacoma

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Gary Morrow

OTHER

NCT00022074 - Gabapentin For the Control of Hot Flashes in Women With Breast Cancer | Biotech Hunter | Biotech Hunter